Literature DB >> 16782025

Th17: an effector CD4 T cell lineage with regulatory T cell ties.

Casey T Weaver1, Laurie E Harrington2, Paul R Mangan3, Maya Gavrieli4, Kenneth M Murphy4.   

Abstract

The naive CD4 T cell is a multipotential precursor with defined antigen recognition specificity but substantial plasticity for development down distinct effector or regulatory lineages, contingent upon signals from cells of the innate immune system. The range of identified effector CD4 T cell lineages has recently expanded with description of an IL-17-producing subset, called Th17, which develops via cytokine signals distinct from, and antagonized by, products of the Th1 and Th2 lineages. Remarkably, Th17 development depends on the pleiotropic cytokine TGF-beta, which is also linked to regulatory T cell development and function, providing a unique mechanism for matching CD4 T cell effector and regulatory lineage specification. Here, we review Th17 lineage development, emphasizing similarities and differences with established effector and regulatory T cell developmental programs that have important implications for immune regulation, immune pathogenesis, and host defense.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16782025     DOI: 10.1016/j.immuni.2006.06.002

Source DB:  PubMed          Journal:  Immunity        ISSN: 1074-7613            Impact factor:   31.745


  512 in total

Review 1.  PKC-θ is a drug target for prevention of T cell-mediated autoimmunity and allograft rejection.

Authors:  Myung-Ja Kwon; Ruiqing Wang; Jian Ma; Zuoming Sun
Journal:  Endocr Metab Immune Disord Drug Targets       Date:  2010-12       Impact factor: 2.895

Review 2.  Maternal immune activation and autism spectrum disorder: interleukin-6 signaling as a key mechanistic pathway.

Authors:  E Carla Parker-Athill; Jun Tan
Journal:  Neurosignals       Date:  2010-10-02

3.  Macrophages participate in IL-17-mediated inflammation.

Authors:  Jobert G Barin; G Christian Baldeviano; Monica V Talor; Lei Wu; Sufey Ong; Farhan Quader; Ping Chen; Dongfeng Zheng; Patrizio Caturegli; Noel R Rose; Daniela Ciháková
Journal:  Eur J Immunol       Date:  2012-01-23       Impact factor: 5.532

4.  Il-1 beta-induced post-transition effect of NF-kappaB provides time-dependent wave of signals for initial phase of intrapostatic inflammation.

Authors:  Eugene V Vykhovanets; Sanjeev Shukla; Gregory T MacLennan; Olena V Vykhovanets; Donald R Bodner; Sanjay Gupta
Journal:  Prostate       Date:  2009-05-01       Impact factor: 4.104

Review 5.  IL-17 in the lung: the good, the bad, and the ugly.

Authors:  Stephen J Gurczynski; Bethany B Moore
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2017-08-31       Impact factor: 5.464

6.  Acute exposure to methamphetamine alters TLR9-mediated cytokine expression in human macrophage.

Authors:  Ariel Burns; Pawel Ciborowski
Journal:  Immunobiology       Date:  2015-09-08       Impact factor: 3.144

7.  The essential role of single Ig IL-1 receptor-related molecule/Toll IL-1R8 in regulation of Th2 immune response.

Authors:  Katarzyna Bulek; Shadi Swaidani; Jinzhong Qin; Yi Lu; Muhammet F Gulen; Tomasz Herjan; Booki Min; Robert A Kastelein; Mark Aronica; Magdalena Kosz-Vnenchak; Xiaoxia Li
Journal:  J Immunol       Date:  2009-03-01       Impact factor: 5.422

8.  NF-kappa B1 p105 regulates T cell homeostasis and prevents chronic inflammation.

Authors:  Mikyoung Chang; Andrew J Lee; Leo Fitzpatrick; Minying Zhang; Shao-Cong Sun
Journal:  J Immunol       Date:  2009-03-01       Impact factor: 5.422

9.  Rapamycin inhibits differentiation of Th17 cells and promotes generation of FoxP3+ T regulatory cells.

Authors:  Heather Kopf; Gonzalo M de la Rosa; O M Zack Howard; Xin Chen
Journal:  Int Immunopharmacol       Date:  2007-09-20       Impact factor: 4.932

10.  IL-17RD (Sef or IL-17RLM) interacts with IL-17 receptor and mediates IL-17 signaling.

Authors:  Zhili Rong; Anan Wang; Zhiyong Li; Yongming Ren; Long Cheng; Yinghua Li; Yinyin Wang; Fangli Ren; Xiaoning Zhang; Jim Hu; Zhijie Chang
Journal:  Cell Res       Date:  2009-02       Impact factor: 25.617

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.